Exercise to Boost Immunity in Advanced Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorSheffield Teaching Hospitals NHS Foundation Trust
About this trial
The trial is a prospective feasibility trial conducted in Sheffield. Recruitment will include twenty patients receiving first line palliative immunotherapy for advanced, unresectable or metastatic mesothelioma and patients receiving first line systemic anti-cancer treatment for pancreatic cancer. Patients will attend the AWRC for a supervised exercise session once a week to include aerobic exercise along with an unsupervised weekly exercise session for 3 months. Blood samples will be collected at baseline and then monthly for 3 months, pre and post the supervised exercise session. Cytokine, myokine and immune cell concentration will be analysed using cytokine bead-based multiplex immune assays and RNA-seq to full profile changes in gene and protein expression
Eligibility criteria
Qualifiers
Patients about to start or who are undergoing first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma or patients about to start or who are undergoing first line palliative chemotherapy for advanced, unresectable, or metastatic pancreatic cancer.
Age over 18 years old
Histological or cytological diagnosis of mesothelioma or pancreatic cancer.
ECOG Performance status 0-1 (to be assessed by clinician)
Disqualifiers
Prior treatment with systemic anti-cancer treatment
More than one primary cancer
Uncontrolled brain or bone metastases
Patients who have progressed on first line palliative immunotherapy for advanced, unresectable, or metastatic mesothelioma.
Trial design
Treatments tested in this trial
- Exercise
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Sheffield Teaching Hospitals NHS Foundation Trust
Lead sponsor
Sheffield Hallam University
Collaborator
University of Sheffield
Collaborator
Source ClinicalTrials.gov